EE457 Major Ischemic or Hemorrhagic Events and Associated Costs Among Anticoagulated Patients with Non-Valvular Atrial Fibrillation in US Health Plans

Abstract

Non-valvular atrial fibrillation (NVAF) is a cardiovascular condition affecting approximately 1% of the United States (US) population and is associated with substantial clinical burden. Current practice guidelines recommend anticoagulants as treatment for NVAF, with direct oral anticoagulants such as apixaban and rivaroxaban having superior adverse event profiles as compared to warfarin. Two comparative effectiveness and safety analyses of apixaban and rivaroxaban among NVAF patients in the US were recently published. Applying findings from these analyses, costs of major ischemic and haemorrhagic events were estimated for apixaban and rivaroxaban from a US payer perspective.